US EditionPublished • loading... • Updated
TYBR Health Announces First U.S. Clinical Use of the B3 GEL™ System
TYBR Health's FDA-cleared B3 GEL System aids post-surgical soft tissue healing by conforming to surfaces and maintaining biomechanical separation, with ongoing real-world evaluation.
- On Jan. 5, 2026, TYBR Health, regenerative medicine and medical device company, announced the first U.S. clinical use of the FDA-cleared B3 GEL System.
- Designed as a collagen-based ECM hydrogel, B3 GEL is a flowable extracellular matrix tissue protector that conforms to tissue surfaces and is naturally resorbed, unlike physical barriers.
- Dr. Hanna Tammam, fellowship-trained hand, elbow, and shoulder surgeon, applied B3 GEL in a complex second-stage flexor tendon reconstruction and two additional flexor tendon repair cases, observing favorable early motion, minimal stiffness, and no complications.
- TYBR Health said it will continue evaluating the B3 GEL System through post-market surveillance and real-world clinical use, with company leaders calling early U.S. cases a pivotal milestone.
- By protecting healing tissues during the critical early healing window, B3 GEL helps bridge surgical repair and functional recovery, while recently published research suggests ECM-based hydrogels may support native repair.
Insights by Ground AI
25 Articles
25 Articles
TYBR Health reports first clinical use of tissue protector in US
TYBR Health has announced the first US clinical use of the collagen-based tissue protector, B3 GEL System, aimed at supporting post-surgical healing.The post TYBR Health reports first clinical use of tissue protector in US appeared first on Medical Device Network.
Coverage Details
Total News Sources25
Leaning Left0Leaning Right0Center13Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
